Remove Business Development Remove Clinical Development Remove Drugs Remove Licensing
article thumbnail

How to get the biopharma deal you want

Drug Discovery World

Dr Neela Patel, Chief Business Officer at Bonum Therapeutics, offers advice on how to negotiate a winning deal in biopharma that meets investors’, buyers’ and sellers’ goals. For pharmas, new programs and portfolios from biotech companies offer a way to augment internal research.

article thumbnail

Ultimovacs Announces the Appointment of Ton Berkien as Chief Business Officer

The Pharma Data

Berkien will join Ultimovacs from his current position at Amgen as Director Global Business Development. At Ultimovacs, he will lead all business and corporate development efforts and continue to maintain and foster connections with leading biotechnology and pharmaceutical companies. “In

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics

The Pharma Data

LNPs are spheric drug delivery bodies which can be equipped with therapeutic payloads for intracellular delivery. Acuitas’ proprietary LNP technology is used in multiple vaccines and therapeutics in clinical development and was also used in some of the COVID-19 vaccines that were approved and administered to people in 180 countries. .

article thumbnail

Everest Medicines Announces Amended Agreement with Spero Therapeutics

The Pharma Data

The companies announced in January 2019 a collaboration agreement to develop, manufacture and commercialize SPR206 in the Territory. SPR206 is in clinical development as an innovative option for the treatment of multi-drug resistant (MDR) Gram-negative bacterial infections. SHANGHAI , Jan. ” About SPR206.

article thumbnail

Bayer Continues Eying Potential Partnerships in Cell and Gene Therapy Space

The Pharma Data

Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, pictured above. Each of the companies met strict criteria that includes assets in clinical development, an industry-leading platform and in-house manufacturing capabilities. “We Photo courtesy of Bayer.

article thumbnail

Bayer acquires Noria and PSMA Therapeutics to expand portfolio in prostate cancer

The Pharma Data

The companies acquired by Bayer, Noria and PSMA Therapeutics, have exclusive world-wide rights to technology licensed from Weill Cornell Medicine (New York, NY, USA) and Johns Hopkins University (Baltimore, MD, USA). Xofigo is currently under further evaluation in a broad clinical development program in prostate cancer and beyond.

article thumbnail

LogicBio Therapeutics Receives FDA Fast Track Designation for LB-001 for the Treatment of Methylmalonic Acidemia (MMA)

The Pharma Data

Food and Drug Administration (FDA) has granted Fast Track designation to its clinical candidate, LB-001 for the treatment methylmalonic acidemia (MMA). Fast Track designation allows for early and frequent communication with the FDA throughout the entire drug development and review process. About LogicBio Therapeutics.